Real-World dupilumab study aims to ease chronic itch

NCT ID NCT05991323

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study follows 100 adults with prurigo nodularis who are already prescribed dupilumab (Dupixent) by their doctor. Researchers will track why patients start or stop the drug, how well it controls itching and skin bumps, and any hospital visits. The goal is to see how dupilumab performs outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dupilumab (Dupixent)
What this could lead to: If successful, this could confirm dupilumab as a reliable long-term treatment for prurigo nodularis, helping reduce itching and skin nodules.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. Dupilumab can cause side effects like injection site reactions or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prurigo nodularis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRURIGO NODULARIS

Contacts and locations

Show contact details

Locations

Allergy Center at Brookstone Research - Centricity Research - PPDS- Site Number : 8400025

Columbus, Georgia, 31904, United States
Center for Dermatology Clinical Research- Site Number : 8400002

Fremont, California, 94538, United States
Dawes Fretzin Clinical Research Group-7910 N Shadeland Ave- Site Number : 8400003

Indianapolis, Indiana, 46250-2041, United States
Derm Institute of Western Michigan- Site Number : 8400034

Caledonia, Michigan, 49316-7478, United States
Dermatology Associates Western Michigan- Site Number : 8400033

Grand Rapids, Michigan, 49546-6204, United States
Duke Dermatology Clinic- Site Number : 8400026

Durham, North Carolina, 27710-4000, United States
GSI Clinical Research- Site Number : 8400017

Margate, Florida, 33063-7011, United States
Golden State Dermatology- Site Number : 8400014

Walnut Creek, California, 94598-3335, United States
Halcyon Dermatology- Site Number : 8400023

Laguna Hills, California, 92653, United States
Investigational Site Number : 1240002

Newmarket, Ontario, L3Y 5G8, Canada
Investigational Site Number : 1240003

Barrie, Ontario, L4M 7G1, Canada
Investigational Site Number : 1240004

Ajax, Ontario, L1S 7K8, Canada
Investigational Site Number : 1240005

Toronto, Ontario, M2M 4J5, Canada
Investigational Site Number : 1240006

Fredericton, New Brunswick, E3B 1G9, Canada
Investigational Site Number : 1240007

Edmonton, Alberta, T5K 2V4, Canada
Investigational Site Number : 1240009

Calgary, Alberta, T2J 7E1, Canada
Investigational Site Number : 1240010

Waterloo, Ontario, N2J 1C4, Canada
Investigational Site Number : 1240011

London, Ontario, N6H 5L5, Canada
Investigational Site Number : 1240012

Surrey, British Columbia, V3R 6A7, Canada
Investigational Site Number : 1560002

Shenzhen, 518000, China
Investigational Site Number : 1560003

Jinan, Shandong, 250001, China
Investigational Site Number : 1560004

Xi'an, Shaanxi, 710004, China
Investigational Site Number : 1560005

Beijing, 100083, China
Investigational Site Number : 1560006

Shanghai, 200020, China
Investigational Site Number : 1560007

Beijing, 100050, China
Investigational Site Number : 1560008

Hangzhou, Zhejiang, 311400, China
Investigational Site Number : 1560009

Guangzhou, Guangdong, 510630, China
Investigational Site Number : 1560010

Wenzhou, Zhejiang, 325000, China
Investigational Site Number : 2500001

Nantes, 44000, France
Investigational Site Number : 2500005

Brest, Finistère, 29606, France
Investigational Site Number : 3920001

Obihiro, Hokkaido, 080-0013, Japan
Investigational Site Number : 3920003

Kyoto, 606-8507, Japan
Investigational Site Number : 3920004

Matsudo, 271-0092, Japan
Investigational Site Number : 5280001

Bergen op Zoom, North Brabant, 4624 VT, Netherlands
Investigational Site Number : 5280002

Hoofddorp, North Holland, 2134 TM, Netherlands
Las Vegas Dermatology- Site Number : 8400027

Las Vegas, Nevada, 89144-0518, United States
Medical Dermatology Specialists Site Number : 8400005

Phoenix, Arizona, 85006-2754, United States
Medical University of South Carolina (MUSC) - PPDS- Site Number : 8400001

Charleston, South Carolina, 29425-8903, United States
Mission Dermatology - Rancho Santa Margarita- Site Number : 8400015

Rancho Santa Margarita, California, 92688-3623, United States
North Texas Center for Clinical Research- Site Number : 8400012

Frisco, Texas, 75034, United States
Oakland Hills Dermatology - 3400 Auburn Rd- Site Number : 8400007

Auburn Hills, Michigan, 48326-3396, United States
Saguaro Dermatology Associates, LLC - Probity - PPDS- Site Number : 8400024

Phoenix, Arizona, 85008-3884, United States
Texas Tech University Health Sciences Center-125 W Hague Rd- Site Number : 8400010

Lubbock, Texas, 79430-0002, United States
Total Vein And Skin, LLC- Site Number : 8400019

Boynton Beach, Florida, 33437-3782, United States
U.S. Dermatology Partners Lee's Summit- Site Number : 8400016

Lee's Summit, Missouri, 64064, United States
U.S. Dermatology Partners Longview- Site Number : 8400032

Longview, Texas, 75601, United States
University of Nebraska - Lauritzen Outpatient Center- Site Number : 8400029

Omaha, Nebraska, 68105-1026, United States
Vivida Dermatology - Flamingo- Site Number : 8400013

Las Vegas, Nevada, 89119, United States
West Virginia Research Institute- Site Number : 8400030

Morgantown, West Virginia, 26505-1873, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.